EP3975987A1 - Pharmazeutische darreichungsformen und verfahren zu deren herstellung - Google Patents
Pharmazeutische darreichungsformen und verfahren zu deren herstellungInfo
- Publication number
- EP3975987A1 EP3975987A1 EP20728084.3A EP20728084A EP3975987A1 EP 3975987 A1 EP3975987 A1 EP 3975987A1 EP 20728084 A EP20728084 A EP 20728084A EP 3975987 A1 EP3975987 A1 EP 3975987A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tablets
- dosage form
- active ingredient
- carrier structure
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Definitions
- the present invention relates to methods of making solid or semi-solid
- Carrier structure is arranged in a 2D or 3D printing device and at least one pharmaceutical active ingredient is applied to at least one section of the carrier structure by a 2D or 3D printing process by means of the printing device.
- the invention also relates to semi-solid or solid dosage forms which can be produced by the method according to the invention.
- FLM filament fusion production
- the object of the present invention is to provide processes for the production of pharmaceutical dosage forms which make it possible to combine the advantages of the classic production of solid or semi-solid dosage forms with those of the production of dosage forms by additive processes.
- the present invention provides a method for producing a solid or semi-solid pharmaceutical dosage form which contains an active ingredient-free carrier structure and at least one pharmaceutical active ingredient applied at least in sections to the carrier structure, comprising the steps:
- one or more pharmaceutical active ingredients are applied to an active ingredient-free carrier with the aid of an additive manufacturing process that is carried out by a two-dimensional (2D) or
- 3D printing process is formed, wherein 2D and 3D printing processes can also be combined.
- the active substance is present in a filament in a fusible filament carrier substance or filament base substance, it being possible or even for several active substances to be used which are present together in one filament or in separate filaments.
- active ingredient-containing filaments are printed at least in sections onto the active ingredient-free carrier structure according to an FFF (filament fusion fabrication) method known per se, for example as described in WO 2016/038356 A1.
- the fusible carrier substance or base substance, which contains the active ingredient (s) is in a different form, preferably as granules, pellets, powder or flakes, which are then produced according to the known FLM (Fused Layer Modeling) method, usually by means of hot melt extrusion by a printing device designed for the FLM process, printed at least in sections on the carrier structure in the form of filaments.
- a binder printing process known per se can be used for printing, preferably for 3D printing, the active pharmaceutical ingredient (s), as described, for example, in EP 2 968 994 A1.
- the active ingredient (s) are present in a powder which, in addition to the active ingredient (s), contains pharmaceutically acceptable auxiliaries adapted to binder jetting, such as binders, antioxidants, fragrances, sweeteners or the like.
- a layer of the powder is applied to the support structure, after which a binding agent fluid is applied to the powder layer by the printing device, the binding agent fluid also being able to be applied to the powder layer in a suitable manner only where the powder can be applied to the powder layer with the aid of the binding fluid of the active ingredient should form on the active ingredient-free carrier structure.
- Excess powder is then removed if necessary.
- the steps of applying the powder layer, at least point-wise or section-wise application of the binder fluid and, if necessary, removal of the excess powder are repeated, and possibly with powders that contain one or more other pharmaceutical active ingredients, until the predetermined three-dimensional arrangement of the active ingredient or the active ingredients on the drug-free carrier structure is created. In a last step, any remaining unbound powder can be removed.
- the additive method for applying the active ingredient or active ingredients is carried out in such a way that the three-dimensional structure of the active ingredient-containing structure on the carrier is carried out by applying individual volume increments (hereinafter also referred to as "voxels") of a fluid, preferably in layers , wherein at least some of the applied volume increments of the fluid contain the active ingredient (s) and the volume increments are preferably applied in layers in such a way that they at least partially touch and solidify after application, so that they have an at least semi-solid, preferably solid, active ingredient-containing structure at least
- the fluid can be, for example, a molten material or at least flowable material or a liquid, the active ingredient-containing volume increment (s) containing the active ingredient (s) in the melted or in any case flowable material or dissolved, dispersed or emulsified in the liquid.
- the applied volume increments are essentially freely definable and can, for example, take on drops, spheres, points, cylinders, cubes, cuboids or other shapes.
- Preferred voxeiforms are, for example, drops and spherical voxels.
- the type (e.g. the above examples) and the size of the volume of the volume increments can be freely combined essentially independently of one another.
- the binding between the individual applied volume increments can take place in different ways.
- the bonding between such voxels can take place through solidification after application to the carrier structure, this being carried out by various mechanisms such as simple cooling and / or chemically using known substances.
- a suitable binder can be added to the voxel material, for example a dispersion or a solution, which, after the voxel has been applied, causes it to harden, the hardening being carried out by the binder, for example, by heat generated by a suitable heat source in the Printing device can be supplied, such as, for example, a light source, preferably a laser device.
- the curing by the binding agent can also take place chemically by means of corresponding starter molecules and / or light of a suitable wavelength, the latter in turn preferably being emitted with the aid of a laser device.
- the fluid of the volume increment can be one or more
- Starting compounds typically monomers, contain one or more polymers, and after the voxel has been applied, suitable means such as, for example,
- light, heat or other polymerization initiators set a polymerization in motion, which hardens the applied voxel and connects it to neighboring voxels.
- the 2D printing process can also be combined with the 3D printing processes described, e.g. by initially at least in sections on the support structure a
- a fluid containing the active ingredient or active ingredients preferably a solution, emulsion or suspension containing the active ingredient (s)
- an active ingredient-free carrier structure i.e. printed.
- the (remaining) fluid e.g. solvent, suspension or emulsion
- Suitable carrier or base materials in particular for the preferred voxel printing process, but also for the FLM / FFF process, in which the
- pharmaceutical active ingredient (s) is / are present are e.g. for a melt extrusion (English hot melt extrusion, HME) usable carriers such as low-melting waxes and
- the HME mixture can contain other processing agents and auxiliaries such as binders, plasticizers, antioxidants, fragrances, sweeteners or the like.
- Suitable HME carriers and plasticizers are, for example, in Crowley et al. (2007) Drug Development and Industrial Pharmacy, 33, pages 909-926 (carrier: pages 917 to 919, in particular Table 1; plasticizers: pages 917 and 920, in particular Table 2), whereby in the present description expressis verbis to the mentioned passages is referred to.
- the additive processes mentioned, in particular the voxel printing process (or “voxel jetting”), are generally and preferably carried out with a computer.
- a calculated two- or three-dimensional image of the object to be printed, but at least the material arrangement to be applied to the optionally provided active substance-free carrier structure with the active substance (s), for example with the aid of a common CAD program, is created.
- the computer-generated representation of the dosage form to be printed or at least the active substance-containing arrangement to be printed on the carrier structure can also be done by scanning an already existing dosage form.
- the computer-generated model image is then subdivided into the desired, in principle freely selectable, volume increments (voxels) at the preferred voxel pressure, the resolution of the real dosage form being greater the smaller the volume increments.
- Printing devices for voxel printing are e.g. in US 2017 / 03,68755 A1 and US 6,070,107.
- the arrangement to be printed or the entire dosage form is divided into corresponding filaments with the aid of a computer.
- step (ii) more than one active ingredient, that is to say two or more active ingredients, is applied in step (ii), it being possible for the active ingredients to be applied together in one step or in several separate partial steps.
- the active ingredients can be applied to the same or different sections of the carrier structure. In this embodiment, the active ingredients can be applied spatially separate from one another or one above the other within a section.
- the invention comprises
- the method also includes applying at least one colored substance by means of 2D and / or 3D printing to at least one section of the carrier structure in such a way that the applied substance is at least one visible on the carrier structure
- the colored substance (s) can be applied separately from the active ingredient (s). It is preferred to apply the color substance (s) together with the pharmaceutical active substance (s). In one embodiment, one substance can thus in each case the area or areas or
- Concentrations of the respective active ingredient are stored, which in turn are reflected by the concentration of the color substance in question.
- different color substances e.g. in one filament in the case of the
- color substance also includes substances that luminesce, in particular fluoresce.
- the information structure caused or formed by the color substance (s) can depict a wide range of information, including several different ones
- the at least one information structure contains information about the type of active substance (s) applied to the carrier structure and / or about the active substances applied to the
- Carrier structure applied amount (s) of active substance and / or via the time or period of intake provided for the dosage form and / or via the date of intake provided for the dosage form and / or via patient-related data (such as name, age, gender, medication and disease (s)) of the patient) and / or via the cost bearer and / or via the attending physician and / or via the pharmaceutical company providing the dosage form and / or via the medical facility supplying the dosage form.
- patient-related data such as name, age, gender, medication and disease (s) of the patient
- the information structure can be selected from a wide range of possible applications.
- the substance or substances can be printed in the form of QR codes, letters and / or numbers. It is of course also possible to print the most varied of patterns such as lines, grids, dots, flat patterns, etc., the preferred embodiment of voxel printing basically offering the most diverse possibilities.
- the printed image of the code can thus contain the active ingredient and at the same time encodes the desired data, as described above, about the patient, doctor, pharmacist and / or medical or pharmaceutical specialist.
- the color substance (s) are, for example, preferably together with the active substance (s) in the printed filament (s) in the filament carrier or base substance.
- the color substance (or several thereof) is preferably together with the active substance (s) in the molten substance
- Base material or the solution or dispersion that is / are used for a given
- solid or semi-solid dosage forms such as tablets, e.g. Oblong tablets, lozenges,
- Implant tablets multiple application tablets, dispersible tablets, prolonged-release tablets, vaginal tablets, eye tablets, coated tablets, matrix tablets, chewable tablets,
- Tablets, capsules, plasters, suppositories or thin films such as ODF products (engl.
- the carrier structure can also be produced by an additive production method, with the above-explained methods of FLM / FFF printing, binder jetting and / or voxel printing preferably being able to be used.
- the carrier structure can therefore first be produced by such a method in a corresponding printing device and presented in such a way that the active ingredient-containing arrangement can then be applied.
- the active ingredient-containing arrangement can then be applied.
- Dosage forms are created, then presented in a suitable 2D or 3D printing device (particularly preferably a printing device designed for voxel printing) and finally the active ingredient-containing arrangement is created on the carrier structure.
- a further aspect of the present invention is formed by semi-solid or solid dosage forms which can be produced by the method according to the invention, preferably the above-mentioned dosage forms.
- the invention thus relates to a solid or semi-solid dosage form which comprises an active ingredient-free carrier structure on which at least one pharmaceutical active ingredient is applied at least in sections in a two- and / or three-dimensional arrangement.
- an active ingredient-free carrier structure on which at least one pharmaceutical active ingredient is applied at least in sections in a two- and / or three-dimensional arrangement.
- more than one pharmaceutical active ingredient that is to say two or more active ingredients
- the active ingredients can be applied separately from one another within a section or spatially one above the other.
- At least one colored substance is also applied to at least one section of the carrier structure in such a way that the applied substance can form at least one information structure that is visible on the carrier structure.
- the at least one information structure containing information about the type of active substance (s) applied to the carrier structure and / or about the active substance (s) applied to the carrier structure
- Patient-related data are preferably selected from the patient's name, age, gender, medication and illnesses.
- the dosage form can be very diverse
- Contain information structures preferably those described in the above
- FIG. 1A to 1D show schematic representations of top views of various exemplary forms of administration of the invention, in which arrangements containing active ingredient were printed on an active ingredient-free flat carrier structure, which include patient-related data or information about the time of administration and the like.
- FIG. 2 shows a photographic representation of a top view of an exemplary
- QR code form of administration of the invention, in which an active ingredient-containing arrangement was printed on an active ingredient-free carrier structure which comprises a QR code.
- a Information structure printed according to the invention in QR code form can in particular serve to increase patient safety and can also advantageously ensure connection to the electronic patient file.
- 3A and 3B show schematic representations of top views of various exemplary forms of administration of the invention in which graphic printing patterns are arranged which, in particular in the case of children and geriatric patients, serve to ensure easy identification of the drug and to increase compliance.
- FIGS. 4A and 4B show schematic representations of top views of various exemplary forms of administration of the invention, in which active ingredient-containing arrangements are applied in partial areas.
- 4A shows a dosage form with pressure fields with different dosages for subsequent adjustment.
- Fig. 4B shows a
- FIG. 5 shows a schematic illustration of a plan view of an exemplary one
- Such embodiments preferably serve to increase the identification of the patient with the device which uses the respective identifier
- the present invention particularly relates to the following aspects and preferred ones
- Dosage form which contains an active ingredient-free carrier structure and at least one pharmaceutical active ingredient applied at least in sections to the carrier structure, comprising the steps:
- step (ii) Applying at least one pharmaceutical active ingredient by 2D and / or 3D printing to at least one section of the surface of the carrier structure in the printing device. 2. The method according to item 1, wherein more than one active ingredient is applied in step (ii), the active ingredients being applied together in one step or in several separate sub-steps.
- the method also comprising applying at least one colored substance by means of 2D and / or 3D printing to at least one section of the carrier structure in such a way that the applied substance is at least one visible on the carrier structure
- Method according to one of the preceding points being a filament fusion production (FFF) method or a fusion layer modeling (FLM) method.
- FFF filament fusion production
- FLM fusion layer modeling
- Volume increments of a fluid are applied, with at least a portion of the applied volume increments of the fluid containing the active ingredient (s) and optionally the color substance (s) and the volume increments solidifying after application.
- step (ii) the following Sub-steps include:
- Evaporation step takes up part of the solution, suspension or emulsion.
- Solid or semi-solid pharmaceutical dosage form containing at least one
- Solid or semi-solid dosage form which comprises an active ingredient-free carrier structure on which at least in sections a two- and / or three-dimensional arrangement is applied which contains at least one pharmaceutical active ingredient.
- Group consisting of name, age, gender, medication and diseases of the patient are selected. 29.
- Dosage form according to item 30. the tablet from the group consisting of oblong tablets, lozenges, implant tablets, multiple-application tablets, dispersed tablets, prolonged-release tablets, vaginal tablets, eye tablets, coated tablets, matrix tablets, chewable tablets, film-coated tablets, modified release tablets ,
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19177751 | 2019-05-31 | ||
PCT/EP2020/065097 WO2020240029A1 (de) | 2019-05-31 | 2020-05-29 | Pharmazeutische darreichungsformen und verfahren zu deren herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3975987A1 true EP3975987A1 (de) | 2022-04-06 |
Family
ID=66685486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20728084.3A Pending EP3975987A1 (de) | 2019-05-31 | 2020-05-29 | Pharmazeutische darreichungsformen und verfahren zu deren herstellung |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220226248A1 (de) |
EP (1) | EP3975987A1 (de) |
JP (1) | JP2022535390A (de) |
CN (1) | CN114206313A (de) |
AU (1) | AU2020282027A1 (de) |
BR (1) | BR112021024026A2 (de) |
CA (1) | CA3142166A1 (de) |
WO (1) | WO2020240029A1 (de) |
ZA (1) | ZA202110948B (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023200954A1 (en) | 2022-04-13 | 2023-10-19 | Aprecia Pharmaceuticals LLC | System and method for additive manufacturing using an omnidirectional magnetic movement apparatus |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6070107A (en) | 1997-04-02 | 2000-05-30 | Stratasys, Inc. | Water soluble rapid prototyping support and mold material |
CN109908355B (zh) | 2013-03-15 | 2022-11-15 | 阿普雷奇亚制药有限责任公司 | 包含左乙拉西坦的快速分散剂型 |
CN111037913B (zh) * | 2014-09-08 | 2022-04-01 | 中央兰开夏大学 | 固体剂型生产 |
JP2019508449A (ja) * | 2016-03-18 | 2019-03-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 種々の効能を有する薬物の組み合わせ |
US10259164B2 (en) | 2016-06-22 | 2019-04-16 | Massachusetts Institute Of Technology | Methods and apparatus for 3D printing of point cloud data |
EP4091796A1 (de) * | 2016-09-09 | 2022-11-23 | Merck Patent GmbH | Verfahren zur herstellung einer festen pharmazeutischen verabreichungsform |
WO2018151725A1 (en) * | 2017-02-15 | 2018-08-23 | Hewlett-Packard Development Company, L.P. | Printed support structure |
-
2020
- 2020-05-29 AU AU2020282027A patent/AU2020282027A1/en active Pending
- 2020-05-29 US US17/615,450 patent/US20220226248A1/en active Pending
- 2020-05-29 CA CA3142166A patent/CA3142166A1/en active Pending
- 2020-05-29 BR BR112021024026A patent/BR112021024026A2/pt unknown
- 2020-05-29 WO PCT/EP2020/065097 patent/WO2020240029A1/de unknown
- 2020-05-29 EP EP20728084.3A patent/EP3975987A1/de active Pending
- 2020-05-29 JP JP2021571555A patent/JP2022535390A/ja active Pending
- 2020-05-29 CN CN202080052075.8A patent/CN114206313A/zh active Pending
-
2021
- 2021-12-24 ZA ZA2021/10948A patent/ZA202110948B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022535390A (ja) | 2022-08-08 |
BR112021024026A2 (pt) | 2022-02-08 |
AU2020282027A1 (en) | 2022-01-27 |
US20220226248A1 (en) | 2022-07-21 |
CA3142166A1 (en) | 2020-12-03 |
CN114206313A (zh) | 2022-03-18 |
ZA202110948B (en) | 2022-08-31 |
WO2020240029A1 (de) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vaz et al. | 3D printing as a promising tool in personalized medicine | |
Trenfield et al. | Binder jet printing in pharmaceutical manufacturing | |
DE69908967T2 (de) | Computer-unterstützer fabrikationsprozess zur schnellen konzeption, prototypenerstellung und herstellung mannigfaltiger medizinischer muster | |
Brambilla et al. | 3DP printing of oral solid formulations: A systematic review | |
Samiei | Recent trends on applications of 3D printing technology on the design and manufacture of pharmaceutical oral formulation: a mini review | |
Acosta-Vélez et al. | 3D pharming: direct printing of personalized pharmaceutical tablets | |
EP3908244B1 (de) | Vorrichtung und verfahren für die tablettierung einer pulverförmigen, flüssigen, pastösen, verkapselten oder granularen wirkstoffzusammensetzung | |
DE102007026969A1 (de) | Verfahren zur Herstellung einer diffraktiven Gitter-Mikrostruktur auf der Oberfläche einer Tablette | |
Seoane-Viaño et al. | 3D printing of pharmaceutical products | |
Desu et al. | 3D printing technology in pharmaceutical dosage forms: advantages and challenges | |
WO2020240029A1 (de) | Pharmazeutische darreichungsformen und verfahren zu deren herstellung | |
EP3975986A1 (de) | Additives verfahren zum dreidimensionalen druck wirkstoffhaltiger objekte | |
EP3975988A1 (de) | Polyvalente darreichungsformen und verfahren zu deren herstellung | |
DE102021202880A1 (de) | Tablette mit zweidimensionaler Kennung | |
DE2604791A1 (de) | Verfahren zur herstellung einer mehrbezirkstablette und tablette, hergestellt nach diesem verfahren | |
WO2021115887A1 (de) | Spotdruckverfahren und -vorrichtung zur additiven herstellung wirkstoffhaltiger darreichungsformen | |
WO2021198308A1 (de) | Vorrichtung und verfahren zur 3d-verdruckung von arzneimittelmischungen zu pharmazeutischen darreichungsformen unter verwendung einer dreh- oder verschiebbaren materialzuführungseinrichtung | |
Nizam et al. | 3D printing in healthcare: a review on drug printing, challenges and future perspectives | |
Pund et al. | 3D Printing Technology: A customized advanced drug delivery | |
Mahmood et al. | Applications of 3D printing for the advancement of oral dosage forms | |
DE19946822A1 (de) | Wirk- und/oder Hilfsstoffe enthaltende Zubereitung mit steuerbarer Freisetzung dieser Stoffe, sowie ihre Verwendung und Herstellung | |
EP4349525A2 (de) | Verfahren zum positionieren eines werkstückes und vorrichtung dafür | |
EP4264617A1 (de) | Verfahren zur herstellung patientenoptimierter darreichungsformen | |
DE102021003906B4 (de) | Verfahren und Vorrichtungen zur Herstellung fester oder halbfester Arzneiformen mit einem mehrschichtigen Aufbau | |
Varghese et al. | Annals of 3D Printed Medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211223 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230627 |